Maslinic acid 5 mg | Purity Not Available
TargetMol
Maslinic acid
Search Results
3′-Hydroxypuerarin 5 mg | 99.33%
TargetMol
3′-Hydroxypuerarin
HMN-176 10 mg | 98.99%
TargetMol
HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1).
More Information Supplier PageHMN-176
HMN-176 25 mg | 98.99%
TargetMol
HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1).
More Information Supplier PageHMN-176
HMN-176 2 mg | 98.99%
TargetMol
HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1).
More Information Supplier PageHMN-176
HMN-176 50 mg | 98.99%
TargetMol
HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1).
More Information Supplier PageHMN-176
HMN-176 5 mg | 98.99%
TargetMol
HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1).
More Information Supplier PageHMN-176
Trifluridine/tipiracil hydrochloride mixture 100 mg | 99.82%
TargetMol
TAS-102 is a novel oral combination drug containing trifluridine (TFT) and Tipiracil hydrochloride (TTP) in a molar ratio of 2:1.
More Information Supplier PageTrifluridine/tipiracil hydrochloride mixture
Trifluridine/tipiracil hydrochloride mixture 10 mg | 99.82%
TargetMol
TAS-102 is a novel oral combination drug containing trifluridine (TFT) and Tipiracil hydrochloride (TTP) in a molar ratio of 2:1.
More Information Supplier PageTrifluridine/tipiracil hydrochloride mixture
Trifluridine/tipiracil hydrochloride mixture 50 mg | 99.82%
TargetMol
TAS-102 is a novel oral combination drug containing trifluridine (TFT) and Tipiracil hydrochloride (TTP) in a molar ratio of 2:1.
More Information Supplier PageTrifluridine/tipiracil hydrochloride mixture